Investing.com -- Citi Research cut its price target on Danish drugmaker Novo Nordisk to 296 Danish crowns from 310 because the company's guidance for "broadly stable" margins through 2030 leaves little room for margin growth, Citi analysts said. Before you buy NVIDIA: our AI model's stock picks are beating the market by 120%+. See the list now » Citi kept its "neutral" rating on the stock. The guidance, driven by research and development (R&D) spending, came at Novo's recent CMD. Citi lowered its adjusted operating profit forecasts for 2028 to 2030 by 2% to 4% as a result. Citi's target now assumes Novo trades at 14 times 2027 earnings, down from 15 times.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.